Larazotide 5mg Research Peptide
Larazotide acetate (AT-1001) is a synthetic octapeptide tight junction regulator developed by Alba Therapeutics (now 9 Meters Biopharma) that acts as a zonulin antagonist, blocking zonulin-mediated opening of intestinal epithelial tight junctions. Zonulin is a protein that physiologically regulates gut permeability, and its dysregulation — associated with elevated gliadin/gluten exposure and gut dysbiosis — has been linked to increased intestinal permeability (“leaky gut”) in celiac disease, inflammatory bowel disease, and other conditions. Larazotide is one of the most studied intestinal tight junction regulators available for research, having progressed to Phase 2b clinical trials in celiac disease. This 5mg vial provides research-grade Larazotide at ≥99% purity, HPLC verified per batch.
Research Background
A Phase 2b randomized controlled trial in celiac disease patients demonstrated larazotide 0.5mg three times daily significantly reduced gastrointestinal symptom scores and celiac disease patient-reported outcome measures versus placebo, despite patients maintaining a gluten-free diet. This established larazotide as the most clinically validated tight junction regulator in published research. Research applications include intestinal permeability models, celiac disease and non-celiac gluten sensitivity research, IBD gut barrier studies, and investigation of the gut-brain axis in conditions where intestinal permeability plays a mechanistic role.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 5mg per vial
- Storage: −20°C, protected from light
- Target: Zonulin antagonist / tight junction regulator
- Molecular Weight: 825.9 Da
Certificate of Analysis
All Larazotide vials are third-party tested by independent ISO-certified laboratories. HPLC validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
